Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Turhal

P3.15-27 Initial Response to First Line Treatment Is the Best Predictor of the Patient Survival in Advanced NSCLC

Journal of Thoracic Oncology

English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology

English

Related publications

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Journal of Thoracic Oncology

English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma

Cancer Research

2013

English

P3.01-44 CYFRA 21-1 as a Predictor to Response to Chemotherapy and Overall Survival in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada

Journal of Thoracic Oncology

English

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives

Pharmacology

2018

English

Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Journal of Experimental and Clinical Cancer Research

Cancer Research

Oncology

2008

English

Identification and Interpretation of Clinical and Quality of Life Prognostic Factors for Survival and Response to Treatment in First-Line Chemotherapy in Advanced Breast Cancer

European Journal of Cancer

Cancer Research

Oncology

2000

English

P3.15-12 Survival Impact of Patient Enrollment in Antineoplastic Drug Trials for Stage IV Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Turhal

P3.15-27 Initial Response to First Line Treatment Is the Best Predictor of the Patient Survival in Advanced NSCLC

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Related publications

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

P3.01-44 CYFRA 21-1 as a Predictor to Response to Chemotherapy and Overall Survival in Patients With Advanced NSCLC

P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Identification and Interpretation of Clinical and Quality of Life Prognostic Factors for Survival and Response to Treatment in First-Line Chemotherapy in Advanced Breast Cancer

P3.15-12 Survival Impact of Patient Enrollment in Antineoplastic Drug Trials for Stage IV Non-Small Cell Lung Cancer (NSCLC)